Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS BIRCH

NPI
1447342647
CMS profile
201323
Location
TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$22.47

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $22.47 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Abbott Laboratories $22.47 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS BIRCH

NPI 1447342647 · CMS profile ID 201323

TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447342647?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS BIRCH, NPI 1447342647, CMS profile ID 201323. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447342647?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). THOMAS BIRCH, NPI 1447342647, CMS profile ID 201323. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447342647?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
THOMAS BIRCH, NPI 1447342647, CMS profile ID 201323, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447342647?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $22.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $22.4711/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671863011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $22.47 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,200.00 1
PY2021 Principal investigator $129,061.68 43
PY2020 Principal investigator $213,574.59 75
PY2019 Principal investigator $56,908.59 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI PASTEUR INC. $11,202.00 12/22/2021 Non-covered Recipient Entity
Holy Name Hospital
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) No dispute reported 06/30/2026 838358439
Principal investigator 1 SANOFI PASTEUR INC. $6,500.00 12/22/2021 Non-covered Recipient Entity
Holy Name Hospital
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) No dispute reported 06/30/2026 838358445
Principal investigator 1 SANOFI PASTEUR INC. $470.00 12/22/2021 Non-covered Recipient Entity
Holy Name Hospital
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) No dispute reported 06/30/2026 838358451
Principal investigator 1 SANOFI PASTEUR INC. $805.00 12/22/2021 Non-covered Recipient Entity
Holy Name Hospital
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) No dispute reported 06/30/2026 838358457
Principal investigator 1 Novo Nordisk AS $1,302.80 11/24/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811482725
Principal investigator 1 Novo Nordisk AS $4,521.80 10/29/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811482715
Principal investigator 1 Novo Nordisk AS $628.00 09/24/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811811771
Principal investigator 1 EMD Serono, Inc. $675.00 09/10/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842910485
Principal investigator 1 EMD Serono, Inc. $1,825.00 09/10/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842911617
Principal investigator 1 EMD Serono, Inc. $1,500.00 09/10/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842912477
Principal investigator 1 Novo Nordisk AS $1,930.81 08/30/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811482705
Principal investigator 1 CSL Behring $120.00 08/18/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819683027
Principal investigator 1 CSL Behring $2,100.00 08/18/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819683029
Principal investigator 1 CSL Behring $3,000.00 08/18/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819683031
Principal investigator 1 Novo Nordisk AS $2,943.74 07/28/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811145653
Principal investigator 1 CSL Behring $16,098.90 07/23/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819683015
Principal investigator 1 Novo Nordisk AS $2,090.93 06/28/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811145693
Principal investigator 1 Incyte Corporation $1,123.50 06/23/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042475
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 06/21/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. No dispute reported 06/30/2026 848751179
Principal investigator 1 CSL Behring $120.00 06/16/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819682951
Principal investigator 1 CSL Behring $500.00 06/16/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819682953
Principal investigator 1 CSL Behring $1,398.60 06/14/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819682949
Principal investigator 1 Amgen Inc. $1,043.55 06/02/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
AMG 407 (OTEZLA) - Ph 3 COVID Consortium Study No dispute reported 06/30/2026 830978449
Principal investigator 1 Incyte Corporation $270.00 06/02/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042405
Principal investigator 1 Incyte Corporation $436.00 06/02/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042419
Principal investigator 1 Incyte Corporation $1,521.00 06/02/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042433
Principal investigator 1 Incyte Corporation $390.00 06/02/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042447
Principal investigator 1 Incyte Corporation $329.00 06/02/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042461
Principal investigator 1 Novo Nordisk AS $2,137.73 05/28/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811145679
Principal investigator 1 Incyte Corporation $2,000.00 05/10/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042391
Principal investigator 1 Incyte Corporation $2,000.00 05/10/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) No dispute reported 06/30/2026 831042501
Principal investigator 1 Novo Nordisk AS $2,202.61 04/26/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811843559
Principal investigator 1 Novo Nordisk AS $250.00 03/24/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811811775
Principal investigator 1 Novo Nordisk AS $9,309.13 03/24/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811811777
Principal investigator 1 Novo Nordisk AS $200.00 02/26/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811145665
Principal investigator 1 Novo Nordisk AS $3,633.75 02/22/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811811773
Principal investigator 1 EMD Serono, Inc. $5,766.30 02/19/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842902663
Principal investigator 1 CSL Behring $21,555.90 02/09/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) No dispute reported 06/30/2026 819682915
Principal investigator 1 EMD Serono, Inc. $6,400.00 02/02/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842902489
Principal investigator 1 EMD Serono, Inc. $2,000.00 02/02/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842902535
Principal investigator 1 EMD Serono, Inc. $595.00 02/02/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842902821
Principal investigator 1 EMD Serono, Inc. $2,308.00 02/02/2021 Non-covered Recipient Entity
Holy Name Medical Center
A Phase II, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants with COVID-19 Pneumonia No dispute reported 06/30/2026 842908875
Principal investigator 1 Novo Nordisk AS $3,357.63 01/28/2021 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
EX9536-4388 No dispute reported 06/30/2026 811811767